Cost-Effectiveness of Sarilumab Versus Adalimumab for Treating Patients with Active Rheumatoid Arthritis- A Markov Model Assessment
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1338
https://www.valueinhealthjournal.com/article/S1098-3015(18)31641-3/fulltext
Title :
Cost-Effectiveness of Sarilumab Versus Adalimumab for Treating Patients with Active Rheumatoid Arthritis- A Markov Model Assessment
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31641-3&doi=10.1016/j.jval.2018.04.1338
First page :
Section Title :
Open access? :
No
Section Order :
592